‘Female Viagra’ Gets FDA Approval; Sprout CEO Says Drug Is More About Desire Than Performance


CNN’s Elizabeth Cohen reports the FDA has approved the drug flibanserin, dubbed “Viagra for women,” to treat sexual dysfunction in premenopausal women.

HSDD, unfortunately said fast sound like HSTD, is the acronym for Hypoactive Sexual Desire Disorder and refers to a woman’s chronic or ongoing lack of interest in sex, to the point that it causes her personal distress or problems in her relationships.

The first drug for HSDD is Flibanserin, manufactured by Sprout Pharmaceuticals, and marketed as Addyi. “Female Viagra” is a misleading term because Flibanserin is indicated to help women regain their sex drive by balancing levels of brain chemicals (dopamine[+], norepinephrine[+] and serotonin[-]), while Viagra works mechanically by causing smooth muscle relaxation that leads to vasodilation and increased blood flow which functionally converts spongy tissue of the penis into an erection. Addyi is the first approved drug to address low sexual desire rather than the deficient physical mechanics causing sexual dysfunction.

Both drugs have side effects that include hypotension. Women will be advised not to take alcohol with Addyi, which could cause hypotension to the point of fainting.


After two rejections, Sprout Pharmaceuticals now has federal approval for the first drug to treat female hypoactive sex-drive disorder. But the FDA is making the company include a “black box warning” about side effects.



Get updates from The Cardinal ALL NEWS FEEDS on Facebook. Just ‘LIKE’ the ‘Arlington Cardinal Page (become a fan of our page). The updates cover all posts and sub-category posts from The Cardinal — Arlingtoncardinal.com. You can also limit feeds to specific categories. See all of The Cardinal Facebook fan pages at Arlingtoncardinal.com/about/facebook …